What Protein Does Pembrolizumab Target?
Pembrolizumab (Keytruda) binds to programmed cell death protein 1 (PD-1), a checkpoint protein on T cells that inhibits immune responses against tumors.[1]
How Does PD-1 Blocking Work?
PD-1 normally interacts with ligands PD-L1 or PD-L2 on cancer cells, dampening T-cell activity. Pembrolizumab's monoclonal antibody binds PD-1 directly, preventing this interaction and unleashing T cells to attack tumors.[1][2]
Why Target PD-1 Over Other Checkpoints?
PD-1 inhibition reactivates exhausted T cells in the tumor microenvironment, effective across cancers like melanoma, lung, and head/neck. Unlike CTLA-4 blockers, PD-1 targets act later in T-cell activation, reducing some autoimmune risks.[2]
Common Cancers Where PD-1 Targeting Matters
Approved for over 30 indications, including non-small cell lung cancer (with PD-L1 testing), MSI-high tumors, and Hodgkin lymphoma. High PD-L1 expression predicts better response.[1]
Differences from PD-L1 Inhibitors Like Atezolizumab
Pembrolizumab blocks PD-1 on T cells; PD-L1 drugs (e.g., Tecentriq) target ligands on tumors. Both disrupt the axis but PD-1 binders may cover PD-L2 interactions too.[2]
Sources
[1]: DrugPatentWatch.com - Pembrolizumab
[2]: FDA Label for Keytruda (pembrolizumab), Section 12.1 Mechanism of Action